ULREMEV
Live / Registered — Registered (as of 03 Nov 2026)
What this means for you
Registered since 03 Nov 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 03 Nov 2032: the §8 declaration of use).
Record
- Serial number
- 50020119
- Registration number
- 8527915
- Mark type
- Word mark
- Filed
- 29 Jul 2026
- Published for opposition
- 15 Sept 2026
- Registered
- 03 Nov 2026
- Next maintenance filing
- §8 declaration of use, due by 03 Nov 2032 (grace period to 03 May 2033)
- Attorney of record
- Christopher M. Hanes
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Anti-infectives; Vaccines
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 03 Nov 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 03 Nov 2026 — REGISTERED-PRINCIPAL REGISTER
- 15 Sept 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Sept 2026 — PUBLISHED FOR OPPOSITION
- 09 Sept 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Aug 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Jul 2026 — ASSIGNED TO EXAMINER
- 29 Jul 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 29 Jul 2026 — APPLICATION FILING RECEIPT MAILED
- 29 Jul 2026 — NEW APPLICATION ENTERED